title: Acute infarct selective MRI contrast agent.
abstract: To determine the infarct affinity of a low molecular weight contrast agent, Gd(ABE-DTTA), during the subacute phase of myocardial infarct (MI). Dogs (n = 7) were examined, using a closed-chest, reperfused MI model. MI was generated by occluding for 180 min the left anterior descending (LAD) coronary artery with an angioplasty balloon. DE-MRI images with Gd(ABE-DTTA) were obtained on days 4, 14, and 28 after MI. Control DE-MRI by Gd(DTPA) was carried out on day 27. T2-TSE images were acquired on day 3, 13 and 27. Triphenyltetrazolium chloride (TTC) histomorphometry validated postmortem the existence of infarct. Gd(ABE-DTTA) highlighted the infarct on day 4, but not at all on day 14 or on day 28, following MI. On day 4, the mean ± SD signal intensity (SI) of infarcted myocardium in the presence of Gd(ABE-DTTA) significantly differed from that of healthy myocardium (45 ± 6.0 vs. 10 ± 5.0, P < 0.05), but it did not on day 14 (11 ± 9.4 vs. 10 ± 5.7, P = NS), nor on day 28 (7 ± 1.5 vs. 7 ± 2.4, P = NS). The mean ± SD signal intensity enhancement (SIE) induced by Gd(ABE-DTTA) was 386 ± 165% on day 4, significantly different from mean SIE on day 14 (9 ± 20%), and from mean SIE on day 28 (12 ± 18%), following MI (P < 0.05). The last two mean values did not differ significantly (P = NS) from each other. As control, Gd(DTPA) was used and it did highlight the infarct on day 27, inducing a mean SIE value of 312 ± 40%. The mean SIE on day 3, 13, or 27 did not vary significantly (P = NS) on the T2-TSE images (114 ± 41%, 123 ± 41%, and 150 ± 79%, respectively). Post mortem, the existence of infarcts was confirmed by TTC staining. The infarct affinity of Gd(ABE-DTTA) vanishes in the subacute phase of scar healing, allowing its use for infarct age differentiation early on, immediately following the acute phase.
authors.affiliation: Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, MCLM 556, Birmingham, AL 35294-0005, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Kirschner
authors.forename: Akos
authors.initials: A
authors.lastname: Varga-Szemes
authors.forename: Tamas
authors.initials: T
authors.lastname: Simor
authors.forename: Pal
authors.initials: P
authors.lastname: Suranyi
authors.forename: Pal
authors.initials: P
authors.lastname: Kiss
authors.forename: Balazs
authors.initials: B
authors.lastname: Ruzsics
authors.forename: Brigitta C
authors.initials: BC
authors.lastname: Brott
authors.forename: Ada
authors.initials: A
authors.lastname: Elgavish
authors.forename: Gabriel A
authors.initials: GA
authors.lastname: Elgavish
mesh_terms: D000818:Animals; D003287:Contrast Media; D003937:Diagnosis, Differential; D004195:Disease Models, Animal; D004285:Dogs; D019786:Gadolinium DTPA; D008279:Magnetic Resonance Imaging; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000473:pathology; D009206:Myocardium / Q000473:pathology*; D009942:Organometallic Compounds; D004369:Pentetic Acid; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013997:Time Factors
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C120791:gadolinium N-(2-butyryloxyethyl)-N'-(2-ethyloxyethyl)-N,N'-bis(N'',N''-bis(carboxymethyl)acetamido)-1,2-ethanediamine; D004369:Pentetic Acid; D019786:Gadolinium DTPA